Inflammasome as a Promising Therapeutic Target
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 250
Special Issue Editor
Interests: cancer; cancer biology; inflammation; mitochondria; endoplasmic reticulum; NLRP3 inflammasome; signal transduction; cell signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The term “inflammasome” was coined to describe a cytoplasmic multiprotein complex that recognizes signals of host cellular distress and regulates the activation of proinflammatory caspases, which drive subsequent immune responses and inflammation. Inflammasomes can be either friend or foe, depending on the cell type and context. The activation of inflammasomes in acute diseases helps to remove dead cells and initiate tissue repair. However, the persistent activation of inflammasomes in chronic diseases is detrimental because it damages tissues. In fact, inflammasomes have been associated with the pathogenesis of multiple diseases, including neurodegenerative diseases (multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease), autoimmune diseases, metabolic disorders, and cancer.
Thus, considering the substantial role of inflammasomes in different inflammatory pathologies, it is not surprising that strategies targeting inflammasomes are a hot topic of research.
The aim of this Special Issue is to collect the latest reports on the role of inflammasomes in several human pathologies, with particular emphasis on the possible therapeutic values in targeting these inflammasomes for the prevention and treatment of these diseases. A greater understanding of the signaling molecules mediating the beneficial and detrimental effects of their activation is needed. This Special Issue will provide insights regarding the clinical relevance of inflammasomes in human diseases, highlighting their therapeutic promise as molecular targets.
We cordially invite authors and investigators to submit their original research articles, communications, and review articles to this Special Issue.
Dr. Sonia Missiroli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammasome
- autoimmune disease
- cancer
- neurodegenerative disease
- target-therapy
- inflammasome inhibitor
- metabolic disorders
